Extended Data Fig. 2: Additional baseline tumor microenvironment features associated with clinical outcome. | Nature Cancer

Extended Data Fig. 2: Additional baseline tumor microenvironment features associated with clinical outcome.

From: PD-L1 blockade in combination with carboplatin as immune induction in metastatic lobular breast cancer: the GELATO trial

Extended Data Fig. 2

(A) Percentage of stromal tumor-infiltrating lymphocytes (sTILs). N = 23 samples. (B) Gene expression of an IFNy signature27. N = 17 samples. (C) Gene expression of an exhausted T-cell signature28. N as in (B). (D) Gene expression of a tertiary lymphoid structure (TLS) signature29. N as in (B). (E) Gene expression of an immune checkpoint signature30. N as in (B). (F) Tumor mutational burden (TMB, mutations per MB) in ER + vs triple-negative ILC. N as in (B). (G) Mutational signatures enriched in metastatic lesions. N as in (B). (A–F) Median with interquartile range, statistics by two-sided Mann-Whitney-U test. Baseline metastatic lesions correspond to metastases presented in Fig. 3 and Extended Data Figs. 3 and 4.

Back to article page